Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA

6/14/24 4:12:53 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EDIT alert in real time by email

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion
Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

Get the next $EDIT alert in real time by email

Recent Analyst Ratings for
$EDIT

Date	Price Target	Rating	Analyst
8/8/2024	$13.00 → $15.00	Neutral → Buy	BofA Securities
5/9/2024	$7.00	Underweight → Equal-Weight	Morgan Stanley
10/24/2023	$11.00	Neutral → Buy	Citigroup
10/18/2023	$8.00	Underweight → Neutral	JP Morgan
10/17/2023		Overweight → Neutral	Cantor Fitzgerald
9/29/2023	$9.00 → $17.00	Hold → Buy	Stifel
6/12/2023	$17.00	Mkt Perform → Outperform	Raymond James
2/1/2023	$15.00	Overweight	Cantor Fitzgerald

More analyst ratings

$EDIT
Leadership Updates

Live Leadership Updates

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into
9/25/23 9:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
8/28/23 7:00:57 AM ET
$EDIT
$MDNA
$TNGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo
7/24/23 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EDIT
Press Releases

Fastest customizable press release news feed in the world

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities. "We are pleased to partner with DRI to monetize a portion of the licensing payments from the Vertex Cas9 license deal we announced last December, providi
10/3/24 6:00:59 PM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 4Time: 4:05 p.m. ETLocation: New York, NY 2024 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 5Time: 4:30 p.m. ETLocation: Boston, MA 2024 Cantor Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, September 17Time: 1:20 p.m. ETLocation: New York, NY Chardan 8t
8/28/24 9:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are hig
8/7/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EDIT
Financials

Live finance-specific insights

Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are hig
8/7/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-800-343-4849 and international callers should dial +1-203-518-9848 approximately five minutes before the call begins.Participants should ask to be connected to the Editas Medicine Earnings Conference Call. The conference call will also be webcast and can be accessed from the "Investors" section of the Editas Medici
7/31/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines Strong financial position with operational runway into 2026 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today r
5/8/24 7:00:00 AM ET
$BMY
$EDIT
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA

Recent Analyst Ratings for $EDIT

$EDIT Leadership Updates

Live Leadership Updates

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

$EDIT Market Insights

Live Market Insights

Unveiling 5 Analyst Insights On Editas Medicine

Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target

Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA

$EDIT SEC Filings

SEC Form 10-Q filed by Editas Medicine Inc.

Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Editas Medicine Inc. filed SEC Form 8-K: Leadership Update

$EDIT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$EDIT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$EDIT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

EVP, CHIEF MEDICAL OFFICER Mei Baisong sold $1,774 worth of shares (518 units at $3.42), decreasing direct ownership by 0.39% to 133,895 units (SEC Form 4)

CEO O'Neill Gilmore Neil sold $5,325 worth of shares (1,555 units at $3.42), decreasing direct ownership by 0.49% to 313,724 units (SEC Form 4)

EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $64,370 worth of shares (11,886 units at $5.42), decreasing direct ownership by 14% to 73,136 units (SEC Form 4)

Editas Medicine upgraded by BofA Securities with a new price target

Editas Medicine upgraded by Morgan Stanley with a new price target

Editas Medicine upgraded by Citigroup with a new price target

$EDIT Press Releases

Fastest customizable press release news feed in the world

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

$EDIT Financials

Live finance-specific insights

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Editas Medicine Announces First Quarter 2024 Results and Business Updates

$EDIT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

Recent Analyst Ratings for
$EDIT

$EDIT
Leadership Updates

$EDIT
Market Insights

$EDIT
SEC Filings

$EDIT
Insider Purchases

$EDIT
Insider Trading

$EDIT
Analyst Ratings

$EDIT
Press Releases

$EDIT
Financials

$EDIT
Large Ownership Changes